Heart failure & cardiomyopathies
Economic burden associated with systemic inflammation in patients with HFmrEF/HFpEF
Authors' conclusion
SI was associated with increased economic and resource burden among patients with HFmrEF/HFpEF. SI testing may have a potential role in identifying those likely to have higher HCRU.
Study context
- Population
- Patients with HFmrEF/HFpEF and a valid high-sensitivity C-reactive protein (hsCRP) test within the Komodo Healthcare Map database between January 2016 and April 2024propensity-weighted patients with HFmrEF/HFpEF and an eligible hsCRP test
- Participants
- 7,242 patients
- Exposure
- with systemic inflammation (SI) vs without SI
- with SIn = 3,299
- without SIn = 3,943
Methodological detailsInverse probability of treatment weighting
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Total medical cost difference, per-patient per-year (adjusted to April 2024 USD) · minimum 12 months following hsCRP test and HF diagnosis
- With SI vs without SI
- total medical cost difference $3,329 (95% CI 1,802–4,857)
- With SI vs without SI
- cost difference, all-cause outpatient visits $1,175 (95% CI 302–2,049)
- With SI vs without SI
- cost difference, hospitalizations $1,666 (95% CI 845–2,488)
Observational data: associations, not effects.
Original publication
Economic burden associated with systemic inflammation in patients with HFmrEF/HFpEF. Am Heart J. Published 3 April 2026. doi:10.
Summarised from the published abstract; every number is checked against it